US pharma’s Chinese biotech deals face uncertainty under Treasury proposal
By Steve Scherer ( October 30, 2026, 12:52 GMT | Comment) -- Proposed US limits on investments in Chinese biotechnology could make American drugmakers less competitive against foreign rivals and disrupt the complex partnerships that have made China an important source of new medicines, experts told MLex. The Treasury proposal would restrict certain equity investments and joint ventures but generally preserve conventional licensing agreements.Proposed US restrictions on investment in Chinese biotechnology could put American drugmakers at a disadvantage to European and Japanese rivals, while forcing changes to the increasingly sophisticated licensing arrangements that have made China a major supplier of experimental medicines, industry experts and legal specialists told MLex....
Prepare for tomorrow’s regulatory change, today
MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.
Know what others in the room don’t, with features including:
- Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
- Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
- Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
- Curated case files bringing together news, analysis and source documents in a single timeline
Experience MLex today with a 14-day free trial.